Key Updates
YOLO recovered 2.01% to $3.31 on December 31st, posting its first gain in ten trading sessions and closing the year with a 36.57% YTD return despite the brutal post-executive order selloff. The modest recovery appears technical in nature following nine consecutive down days that saw the ETF decline 33% from its December 18th peak. A Wall Street Journal analysis published December 30th reveals the depth of the industry's tax burden: the top eight U.S. multistate operators have accumulated $2.6 billion in tax liabilities from 2019 through September 2025, with only $600 million paid, underscoring the critical importance of 280E relief that rescheduling would provide. The year-end bounce suggests capitulation selling may be exhausting, though no fundamental catalysts emerged to support sustained recovery.
Current Trend
YOLO remains in a severe downtrend following the December 18th executive order announcement, declining 33% from its $4.95 intraday peak despite the policy representing the most significant federal cannabis reform in decades. The ETF's YTD performance of 36.57% masks the dramatic volatility, with the entire 6-month gain of 74.41% concentrated in November-December anticipatory buying before the executive order signing. The 1-month performance of 11.28% reflects the net effect of the pre-announcement rally and subsequent collapse. Current price of $3.31 sits near the low end of recent trading range, with the ETF having established resistance at $3.50-$3.60 during the selloff. Support appears around $3.20-$3.25 based on December lows. The modest 2.01% gain on December 31st represents potential stabilization after extreme selling pressure, though volume and conviction remain weak heading into year-end.
Investment Thesis
The investment thesis centers on federal cannabis rescheduling from Schedule I to Schedule III eliminating Section 280E tax provisions that create effective tax rates of 60-90% for cannabis companies, potentially bringing rates to the 20% range seen in other industries. The December 18th executive order provides the policy framework, though implementation timing remains uncertain with no specific deadline established. The fundamental opportunity is quantifiable: the top eight U.S. multistate operators carry $2.6 billion in accumulated tax liabilities, representing massive balance sheet relief once 280E is eliminated. Additionally, rescheduling opens access to traditional banking, institutional capital, and potential Medicare reimbursement for CBD products starting April 2025. The U.S. cannabis market generated $34 billion in 2024 retail sales with 425,000 workers, operating across 40 states with medical programs and 24 with recreational legalization. However, the thesis faces execution risk around implementation timing, continued margin compression in state markets, and the paradox that the most significant policy victory in cannabis history triggered a 33% selloff, suggesting "buy the rumor, sell the news" dynamics may persist.
Thesis Status
The thesis remains fundamentally intact but faces a critical timing gap between policy announcement and actual implementation. The executive order signed December 18th provides no specific timeline, with Alliance Global Partners noting that a final rule by year-end 2025 would be critical for companies to secure 2025 tax savings. The violent market reaction—a 27% decline on announcement day per WSJ—reveals investor skepticism about whether rescheduling will actually occur and concern about options-driven volatility. The thesis assumes material improvement in operating margins and cash flow from 280E elimination, but U.S. cannabis gross margins have declined approximately 10 percentage points since 2021, indicating structural challenges beyond taxation. The December 31st stabilization at $3.31 suggests the worst of the selloff may have passed, but the thesis now requires concrete implementation progress and evidence that tax relief translates to improved financial performance rather than simply reducing accumulated liabilities.
Key Drivers
The Wall Street Journal's December 30th analysis quantifies the tax burden: top eight multistate operators accumulated $2.6 billion in tax liabilities from 2019-September 2025, with only $600 million paid, creating effective tax rates of 60-90% versus potential 20% rates post-rescheduling. This represents the core financial impact of 280E elimination. Implementation timing remains the critical unknown, with analysts focused on whether a final rule arrives by year-end 2025 to enable companies to claim 2025 tax savings. The Medicare pilot program for CBD products starting April 2025 could attract pharmaceutical companies seeking federally insured revenue streams, per CNBC reporting. However, margin compression continues with gross margins down 10 percentage points since 2021, representing "the most margin-compressed period the legal cannabis industry has ever seen." The year-end bounce appears purely technical following nine consecutive down days rather than driven by new fundamental developments.
Technical Analysis
YOLO closed at $3.31 on December 31st, up 2.01% in its first gain after nine consecutive losing sessions that erased 33% of value. The ETF established a clear downtrend channel from the December 18th peak of approximately $4.95 to current levels, with resistance forming at $3.50-$3.60 during the selloff and support appearing around $3.20-$3.25. The 1-month gain of 11.28% reflects the November-December rally before the executive order signing, while the 6-month surge of 74.41% captures the entire anticipatory run from summer lows. Volume patterns during the December selloff suggest institutional distribution and options-related selling rather than retail panic. The modest year-end recovery on light volume indicates potential exhaustion of selling pressure but lacks conviction for sustained reversal. Key technical levels: immediate resistance at $3.50, major resistance at $3.75-$4.00 (pre-selloff consolidation zone), support at $3.20-$3.25, and critical support at $3.00 psychological level. The ETF would need to reclaim $3.75 on strong volume to signal genuine trend reversal versus dead-cat bounce dynamics.
Bull Case
- Section 280E elimination could unlock $2.6 billion in accumulated tax liabilities for top eight multistate operators, with effective tax rates potentially dropping from 60-90% to approximately 20%, dramatically improving cash flow and enabling debt reduction or growth investment.
- Medicare pilot program for CBD products starting April 2025 opens federally insured revenue streams, with 34 million Medicare Advantage beneficiaries potentially eligible and industry experts suggesting valuations "could double or triple" from institutional capital access.
- Schedule III reclassification expected to expand access to traditional banking and financial services, potentially restarting congressional conversations around SAFER Banking Act and reducing capital costs for operators.
- National cannabis retail market has tripled since 2019 to $34 billion in 2024, demonstrating sustained consumer demand despite regulatory headwinds, with enforcement against unlicensed operators potentially benefiting licensed dispensaries.
- The 33% selloff from December 18th peak represents extreme bearish sentiment exhaustion with YOLO now trading near 6-month support levels, creating asymmetric risk-reward for investors with 12-24 month time horizons as implementation details emerge throughout 2025.
Bear Case
- The 27% single-day decline on executive order announcement demonstrates "buy the rumor, sell the news" dynamics and investor skepticism about actual implementation, with no specific timeline provided and historical precedent of cannabis policy reforms stalling.
- U.S. cannabis gross margins declined approximately 10 percentage points since 2021, representing "the most margin-compressed period the legal cannabis industry has ever seen," indicating structural oversupply and pricing pressure that taxation relief alone cannot resolve.
- Implementation timing uncertainty creates risk that 2025 tax savings may not materialize, with Alliance Global Partners noting year-end 2025 deadline as critical but executive order providing no specific timeline for final rule.
- Cannabis remains federally illegal as controlled substance even under Schedule III, and U.S. cannabis companies still cannot list on major stock exchanges, limiting institutional access and liquidity despite rescheduling.
- The cannabis industry has faced bankruptcy cases like MedMen in 2024 due to existing federal restrictions, and accumulated debt burdens may limit companies' ability to capitalize on improved tax treatment even if 280E is eliminated.